Gina M. Mantia-Smaldone, MD
- Request Appointment
- Clinical Locations
- Education, Training & Credentials
- Patient Stories
- Research Profile
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Minimally invasive surgery (laparoscopy and robotic surgery); endometrial cancer and hyperplasia; cervical cancer and dysplasia; vulvar cancer and dysplasia; vaginal cancer and dysplasia; gestational trophoblastic disease; surgical management of pelvic masses
I am excited to be a part of the gynecologic cancer patient care team at Fox Chase Cancer Center. I chose to work at Fox Chase to provide comprehensive, cutting-edge oncologic care by translating advances in research directly into my clinical practice.
As a gynecologic oncologist, I specialize in the surgical and medical management of tumors of the uterus, cervix, ovary, fallopian tube, vulva and vagina. I have extensive experience with complex open, laparoscopic and robotic surgery, which allows me to tailor a surgical plan based upon a patient’s needs and preferences. I also have expertise in administering intravenous and intraperitoneal chemotherapy for gynecologic malignancies. As a member of the multidisciplinary gynecologic cancer patient care team, I work closely with my colleagues in medical and radiation oncology to develop a comprehensive treatment plan that offers the best chance of cure for each patient.
I appreciate the challenges and commitment necessary to care for cancer patients. I understand that a cancer diagnosis can be overwhelming for patients and their families, and I always treat patients how I would want my family members to be treated: with honesty and compassion. I devote the time necessary to educate my patients on their options so they are best able to make an informed decision about their treatment.
Professionally, my research interests focus on endometriosis-associated ovarian cancer and hereditary ovarian cancer, including those resulting from BRCA1 or 2 mutations. The abundant resources available at Fox Chase, as well as my research experiences during my postdoctoral fellowship at the Magee-Womens Research Institute and as a clinical fellow at the University of Pennsylvania allow for me to participate in translational research and investigate innovative therapies to improve the quality of life for women with gynecologic malignancies.
- Clinical Fellow, Gynecologic Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, 2010-2013
- Fellow, Ovarian Cancer Immunology, Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, 2008-2010
- Resident, Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA, 2004-2008
- MD, State University of New York at Stony Brook School of Medicine, Stony Brook, NY, 2004
- BA, Biochemistry and Molecular Biology, Boston University, Boston, MA, 2000
- American Board of Obstetrics and Gynecology
- American College of Obstetrics and Gynecology
- American Association for Cancer Research
- Alpha Omega Alpha
- American Association for Cancer Research
- Society of Gynecologic Oncology
In September of 2015, Diane noticed something unusual - blood in her stool. Obviously concerned, she made an appointment with her local gastroenterologist who performed a colonoscopy in March of 2015. The test revealed a 2-inch bleeding polyp on her colon. The doctor initially diagnosed Diane with hemorrhoids because she had none of the common symptoms of colon cancer such as weight loss or stomach pain.
In October 2012, Patti and Michael Rose were enjoying parenthood, busy raising seven active children, ranging in ages from 2-18. Most women begin annual mammography at the age of 40. Patti, who was 36, never had a mammogram. After she detected a marble-sized lump in her breast, she scheduled her first mammogram and ultrasound, which was followed with a biopsy. Within five days, Patti learned she had breast cancer.
“Fox Chase Cancer Center is the best – and we’re so fortunate it is right around the corner.”
In June 2010, at the age of 35, Jennifer Gilbert felt alone in the world. Her brother was suffering from a terminal brain disease (and died two and half years later), her father passed away and her mother was caring for her grandmother in South Carolina. This recently divorced young woman accepted a new job as a veterinarian tech at a horse hospital in New Jersey where she didn’t know a soul. That’s when she began to experience uncontrollable bleeding and pain, which continued for several months.
- Fertility and gynecologic cancers
- Endometriosis-related ovarian cancer
- Hereditary ovarian cancer
- Immunotherapy and ovarian cancer
Wright AA, Cronin A, Milne DE, Bookman MA, Burger RA, Cohn DE, Cristea MC, Griggs JJ, Keating NL, Levenback CF, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland JC, Weeks JC, O'Malley DM. Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2015 Sep 10;33(26):2841-7. doi: 10.1200/JCO.2015.61.4776. Epub 2015 Aug 3.
Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, Adams SF. CTLA-4 Blockade Synergizes with PARP inhibition in BRCA1-deficient Ovarian cancer. Cancer Immunol Res. 2015 Jul 2. [Epub ahead of print]
Suryawanshi S, Budiu R, Elishaev E, Zhang L, Kim S, Tseng G, Mantia-Smaldone G, Ma T, Donnellan N, Lee T, Mansuria S, Edwards RP, Huang X and Vlad AM. Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res. 2014 Dec 1;20(23):6163-74. doi: 10.1158/1078-0432.CCR-14-1338. Epub 2014 Oct 7.
Mantia-Smaldone G, Ronner L, Blair A, Gamerman V, Morse C, Orsulic S, Rubin S, Gimotty P and Adams SF. The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1-deficienct ovarian tumors and can be exploited to improve treatment response in a mouse model. Gynecol Oncol. 2014 Jun;133(3):584-90. doi: 10.1016/j.ygyno.2014.03.565. Epub 2014 Mar 27.
Mantia-Smaldone G, Bagley LJ, Kasner SE and Chu CS. Vertebral artery dissection and cerebral infarction in a patient with recurrent ovarian cancer receiving bevacizumab. Gynecologic Oncology Case Reports. Volume 5, August 2013, 37-39. http://dx.doi.org/10.1016/j.gynor.2013.04.002.
Chiang CL, Kandalaft L, Tanyi J, Hagemann A, Motz G, Svoronos N, Smith L, Montone K, Mantia-Smaldone G, Nisenbaum H, Torigian D, Levine B, Mick R, Kalos M, Czerniecki B, Powell D, and Coukos G. A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside. Clin Cancer Res. 2013 Jul 15 [Epub ahead of print]
Mantia-Smaldone GM and Chu CS. A Review of Dendritic Cell Therapy for Cancer: Progress and Challenges. BioDrugs. 2013 Oct;27(5):453-68. doi: 10.1007/s40259-013-0030-9.
Suryawanshi S, Vlad AM, Lin H, Mantia-Smaldone G, Laskey R, Lee M, Lin Y, Donnellan N, Klein-Patel M, Lee T, Mansuria S, Elishaev E, Budiu R, Edwards R, and Huang X. Plasma microRNAs as Novel Biomarkers for Endometriosis and Endometriosis-Associated Ovarian Cancer. Clin Cancer Res. 2013 Mar 1; 19(5): 1213-24.
Mantia-Smaldone G, Corr B and Chu CS. Immunotherapy in Ovarian Cancer. Human Vaccines & Immunotherapeutics. 2012 Sep 1; 8(9). 2012 Sep; 8(9):1179-91. doi: 10.4161/hv.20738. Epub 2012 Aug 21.
Mantia-Smaldone GM, Edwards RP and Vlad AM. Targeted treatment of recurrent platinum resistant ovarian cancer: current and emerging therapies. Cancer Management and Research. 2011(3): 25-38. doi: 10.2147/CMR.S8759. Epub 2010 Dec 30.